Conciseness

Most tokens are operational (tool table, IC50/rank thresholds, supertype frequencies, CLI invocations with expected output), and domain judgment Claude would not reliably reproduce (T1–T4 evidence grading, 'MHC binding ≠ immunogenicity') is genuinely additive. Minor trimmable padding remains — e.g. 'B-cell epitopes trigger antibody production' and 'MHC-I epitopes (CD8+ cytotoxic T cells — kill infected cells)' restate textbook immunology — which fits the efficient-with-minor-over-explanation anchor, not the some-unnecessary-explanation level below.

Actionability

Phases 0–3 give concrete tool calls with real argument values (method='netmhcpan_el', length=9, NCBITaxon filters), thresholds with explicit include/consider/exclude actions, and copy-paste-ready `scripts/population_coverage.py` commands whose output format is shown — close to the fully-executable anchor. Phase 4 is the gap: 'PubMed_search_articles(query="[pathogen] [protein] sequence variation strains")' and 'EnsemblVEP_annotate_hgvs(hgvs_notation="[variant_in_epitope]")' are template placeholders without a concrete conservation-checking recipe, which is why it is not a 5.

Workflow Clarity

The six-phase pipeline is clearly sequenced with an ASCII flow diagram, and decision points carry explicit thresholds and actions (coverage 50–70% → 'Redesign with broader HLA coverage'; <80% conservation → 'avoid'). These function as checkpoints, but there are no explicit validate-and-retry loops (e.g., re-running coverage after adding epitopes for uncovered HLA types is only implied by the 'Action' column), matching clear-sequence-with-minor-validation-gaps rather than the explicit-feedback-loops anchor.

Progressive Disclosure

The single bundle file (scripts/population_coverage.py) is referenced by correct path, its purpose and limitations are accurately described in the body, and its CLI usage is shown — references are clear and one level deep. All remaining content (interpretation tables, supertype lists, construct-design principles) is inline in a ~230-line SKILL.md; some of it (e.g., per-phase interpretation tables) could live in a reference file, which is the minor organization gap that keeps this at 4 rather than the well-split overview anchor at 5.

Specificity

The description enumerates multiple concrete actions — 'MHC-I/MHC-II epitope prediction (IEDB)', 'population HLA coverage optimization', 'B-cell epitope identification', and 'cross-strain conservation analysis' — matching the comprehensive-coverage anchor rather than the several-actions-with-gaps level below. It stays in third-person voice throughout.

Completeness

It explicitly answers both questions: the 'what' is the leading capability list ('Computational vaccine candidate design: peptide/subunit vaccines via...') and the 'when' is a concrete 'Use for vaccine epitope prediction, HLA allele coverage, multi-epitope construct design...' clause — the exact structure of the anchor-5 example.

Trigger Term Quality

'vaccine epitope prediction', 'HLA allele coverage', 'multi-epitope construct design', and 'immunogenicity assessment' are natural phrasings for this domain, but common variations users would say — 'vaccine design', 'T-cell epitopes', 'peptide vaccine' — are absent, so it falls just short of the comprehensive-synonyms anchor.

Distinctiveness Conflict Risk

The vaccine-design framing ('multi-epitope construct design', 'cross-strain conservation analysis') carves a clear niche with minimal conflict risk, but generic trigger phrases like 'epitope prediction' and 'immunogenicity assessment' could plausibly fire for adjacent epitope/immunology skills, keeping it at mostly-distinct rather than fully distinct.